FDA approves Sun's generic form of cancer drug Eloxatin

03/11/2010 | Google

The FDA approved Sun Pharmaceutical Industries' generic version of Eloxatin, a colon and rectal cancer treatment from Sanofi-Aventis. The approval allowed Sun subsidiary Caraco Pharmaceutical Laboratories to launch a 50- and a 100-milligram formulation of the drug, also known as oxaliplatin.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care